{"id":"https://openalex.org/W2259707804","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","title":"Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy","display_name":"Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2259707804","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","mag":"2259707804"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.4679","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109239208","display_name":"Miah Hiang Tay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. H. Tay","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020223699","display_name":"Daniel J. George","orcid":"https://orcid.org/0000-0003-1499-7203","observed_orcids":["https://orcid.org/0000-0003-1499-7203","https://orcid.org/0000-0002-0836-8542"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. J. George","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024482335","display_name":"Timothy D. Gilligan","orcid":"https://orcid.org/0000-0003-2308-9303","observed_orcids":["https://orcid.org/0000-0003-2308-9303"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. D. Gilligan","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. M. Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. M. Kelly","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011421087","display_name":"L. Appleby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Appleby","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023517416","display_name":"Mary\u2010Ellen Taplin","orcid":"https://orcid.org/0000-0002-3384-0300","observed_orcids":["https://orcid.org/0000-0002-3384-0300"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.-E. Taplin","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054284633","display_name":"Philip G. Febbo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. G. Febbo","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056766924","display_name":"Philip W. Kantoff","orcid":"https://orcid.org/0000-0001-7275-0597","observed_orcids":["https://orcid.org/0000-0001-7275-0597"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. W. Kantoff","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078027978","display_name":"William K. Oh","orcid":"https://orcid.org/0000-0001-5113-8147","observed_orcids":["https://orcid.org/0000-0001-5113-8147"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. K. Oh","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"4679","last_page":"4679"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.8870000243186951},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9710000157356262},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.9449999928474426},{"id":"https://openalex.org/keywords/docetaxel-refractory-disease","display_name":"docetaxel-refractory disease","score":0.8999999761581421},{"id":"https://openalex.org/keywords/neuroendocrine-differentiation","display_name":"neuroendocrine differentiation","score":0.8690000176429749},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.9319999814033508},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5619999766349792},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.7419999837875366},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.979430079460144},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8893201351165771},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.8740445971488953},{"id":"https://openalex.org/C2780201970","wikidata":"https://www.wikidata.org/wiki/Q412939","display_name":"Estramustine","level":5,"score":0.8251324892044067},{"id":"https://openalex.org/C2780923524","wikidata":"https://www.wikidata.org/wiki/Q239426","display_name":"Mitoxantrone","level":3,"score":0.7556542158126831},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.722387433052063},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5910139083862305},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5312395095825195},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.5299360156059265},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.4610326588153839},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4445866644382477},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.41288822889328003},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3582592010498047},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.20040374994277954},{"id":"https://openalex.org/C2994223898","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate disease","level":4,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.4679","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.4679","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.4679","doi":"https://doi.org/10.1200/jco.2004.22.90140.4679","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.4679","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2048946840","https://openalex.org/W2280491699","https://openalex.org/W2531942420","https://openalex.org/W1990875800","https://openalex.org/W2270261142","https://openalex.org/W2027902748","https://openalex.org/W2383476884","https://openalex.org/W1988594450","https://openalex.org/W2594975421","https://openalex.org/W2467627677"],"abstract_inverted_index":{"4679":[0],"Background:":[1],"Chemotherapy":[2],"is":[3,37,220],"now":[4],"increasingly":[5],"used":[6,14],"in":[7,35,49,56,163,171,178,283],"HRPC":[8,36,57,88,266,304],"management.":[9],"The":[10,181,192,279],"two":[11,294],"most":[12],"frequently":[13],"regimens":[15],"are":[16,25],"mitoxantrone-prednisone":[17],"(MP)":[18],"and":[19,72,95,109,124,145,169,174,189,200,209,215,233],"docetaxel-estramustine":[20],"(DE)":[21],"beyond":[22],"which":[23,311],"options":[24],"limited.":[26],"One":[27],"of":[28,41,66,100,128,140,151,194,226,292,301],"the":[29,42,67,129,230,293],"potential":[30],"reasons":[31],"for":[32,120,212,244,303],"disease":[33],"progression":[34],"increased":[38],"neuroendocrine":[39],"differentiation":[40],"disease.":[43],"Although":[44],"carboplatin,":[45],"a":[46,59,288,316],"drug":[47],"active":[48],"neuroendocrinally":[50],"differentiated":[51],"tumor,":[52],"has":[53,276,318],"modest":[54,277],"activity":[55],"as":[58],"single":[60],"agent,":[61],"we":[62],"retrospectively":[63],"report":[64],"3":[65,115,127,216,259,285],"4":[68,84,113,130,152,261],"patients":[69,85,131,153,213,286,305],"consecutively":[70],"treated":[71,103],"responded":[73],"with":[74,86,104,138,176],"salvage":[75],"docetaxel-carboplatin":[76],"(DC)":[77],"following":[78],"failure":[79],"to":[80,239,251,270],"docetaxel-based":[81],"chemotherapy.":[82],"Methods:":[83],"metastatic":[87],"who":[89,306],"had":[90,132,307],"failed":[91,308],"docetaxel":[92,105,234,253,313],"based":[93],"chemotherapy":[94,101],"at":[96,106,111,223],"least":[97],"one":[98,245],"line":[99],"were":[102,118,197,256],"60\u201370":[107],"mg/m2":[108,241],"carboplatin":[110,273],"AUC":[112],"given":[114],"weekly.":[116],"Patients":[117],"monitored":[119],"measurable":[121],"PSA":[122,135,183,195],"response":[123,196,281],"toxicity.":[125],"Results:":[126],">":[133],"50%":[134,190],"decrease,":[136],"together":[137],"improvement":[139],"performance":[141],"status,":[142],"weight":[143],"gain":[144],"decrease":[146,184],"pain":[147],"medication.":[148],"Median":[149],"age":[150],"was":[154,185,206,229,242,249],"73":[155],"years":[156],"old.":[157],"Prior":[158],"treatments":[159],"include":[160],"D":[161],"alone":[162],"patient":[164,172,179,218,248],"1,":[165],"MP,":[166],"epothilone":[167],"analogue":[168],"DE":[170,175],"2":[173,214],"bevacizumab":[177],"3.":[180],"mean":[182],"74%":[186],"(97%,":[187],"75%":[188],"respectively).":[191],"durations":[193],"20,":[198],"10":[199],"32":[201],"weeks":[202,208,211,225],"respectively.":[203],"Overall":[204],"survival":[205],"20":[207],"63":[210],"while":[217,246],"1":[219],"still":[221,268],"alive":[222],"36":[224],"follow-up.":[227],"Fatigue":[228],"main":[231],"toxicity":[232],"dose":[235],"reduction":[236],"from":[237],"60":[238],"50":[240],"required":[243],"another":[247],"switched":[250],"weekly":[252],"schedule.":[254],"There":[255],"no":[257],"grade":[258],"or":[260,324,327],"hematologic":[262],"toxicities.":[263],"Conclusions:":[264],"Docetaxel-refractory":[265],"may":[267],"respond":[269],"DC,":[271],"though":[272],"by":[274],"itself":[275],"activity.":[278],"significant":[280],"seen":[282],"these":[284],"suggest":[287],"possible":[289],"synergistic":[290],"effect":[291],"drugs.":[295],"A":[296],"prospective":[297],"phase":[298],"II":[299],"trial":[300],"DC":[302],"prior":[309],"chemotherapies":[310],"included":[312],"(but":[314],"not":[315],"platinum)":[317],"been":[319],"initiated.":[320],"Author":[321],"Disclosure":[322],"Employment":[323],"Leadership":[325],"Consultant":[326],"Advisory":[328],"Stock":[329],"Ownership":[330],"Honoraria":[331],"Research":[332],"Funding":[333],"Expert":[334],"Testimony":[335],"Other":[336],"Remuneration":[337],"Aventis":[338,339],"Bristol-Myers":[340],"Squibb":[341]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}